

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 May 2025 (08.05.2025)



(10) International Publication Number
WO 2025/096087 A9

(51) International Patent Classification:
C12N 15/113 (2010.01) A61K 31/7088 (2006.01)

(21) International Application Number:
PCT/US2024/048110

(22) International Filing Date:
24 September 2024 (24.09.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/546,362 30 October 2023 (30.10.2023) US
63/546,965 02 November 2023 (02.11.2023) US

(71) Applicant: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(72) Inventors: **PARIKSHAK, Neelroop**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **FERREIRA, Manuel Allen Revez**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **CAMPOS, Adrian**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **UDEOCHU, Joe**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **ZAMOLODCHIKOV, Daria**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **ALESSANDRI-HABER, Nicole**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **BARAS, Aris**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(74) Agent: **LEGAARD, Paul K.** et al.; Armstrong Teasdale LLP, 7700 Forsyth Boulevard, Suite 1800, St. Louis, Missouri 63105 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(48) Date of publication of this corrected version:

28 August 2025 (28.08.2025)

(15) Information about Correction:

see Notice of 28 August 2025 (28.08.2025)

(54) Title: TREATMENT OF MYELOID CELL DYSFUNCTION WITH MEMBRANE SPANNING 4-DOMAINS A6A (MS4A6A) INHIBITORS

(57) Abstract: The present disclosure generally relates to the treatment of subjects having myeloid cell dysfunction or at risk of developing myeloid cell dysfunction by administering a Membrane Spanning 4-Domains A6A (MS4A6A) inhibitor and/or a Membrane Spanning 4-Domains A64A (MS4A4A) inhibitor to the subject.

WO 2025/096087 A9